Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2130

1.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.
4.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
5.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
6.
7.

Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.

Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, Airoldi M, Suter F.

Clin Infect Dis. 2005 Jan 1;40(1):158-63. Epub 2004 Dec 6.

PMID:
15614706
8.

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group..

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36.

PMID:
11464141
9.
10.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
11.

Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.

Skowron G, Street JC, Obee EM.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):313-9.

PMID:
11707666
12.

Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients.

Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD; EuroSIDA Study Group..

AIDS. 2001 Dec 7;15(18):2385-95.

PMID:
11740189
13.

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.

Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC.

Clin Infect Dis. 2006 Jan 15;42(2):252-9. Epub 2005 Dec 12.

PMID:
16355337
14.

Effect of adherence to newly initiated antiretroviral therapy on plasma viral load.

Gross R, Bilker WB, Friedman HM, Strom BL.

AIDS. 2001 Nov 9;15(16):2109-17.

PMID:
11684930
15.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD..

PLoS One. 2006 Dec 20;1:e89.

16.

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A.

AIDS. 1999 May 28;13(8):951-6.

PMID:
10371176
17.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
18.

A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.

Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.

HIV Med. 2005 Sep;6(5):353-9. Erratum in: HIV Med. 2005 Nov;6(6):426.

19.

Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice.

Moreno A, Perez-Elías MJ, Casado JL, Muñoz V, Antela A, Dronda F, Navas E, Fortún J, Quereda C, Moreno S.

Antivir Ther. 2000 Dec;5(4):243-8.

PMID:
11142618
20.

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.

Antivir Ther. 2008;13(7):927-36.

PMID:
19043927

Supplemental Content

Support Center